Emflaza

Emflaza
製造元: Lupin

Emflazaは、満5歳以上の患者のデュシェンヌ型筋ジストロフィー(DMD)の治療のために指示されたコルチコステロイドである。

6mg

パッケージ 節約 あたり タブレット 価格 ご注文
180 タブレット ¥ 33487.49 ¥ 105.23 ¥ 18941.02
120 タブレット ¥ 20384.00 ¥ 121.40 ¥ 14568.33
90 タブレット ¥ 13103.48 ¥ 145.68 ¥ 13110.77
60 タブレット ¥ 6551.74 ¥ 182.07 ¥ 10924.43
30 タブレット ¥ 291.27 ¥ 8738.08

24mg

パッケージ 節約 あたり タブレット 価格 ご注文
120 タブレット ¥ 14546.47 ¥ 667.99 ¥ 80158.62
  • 無料航空便配送
90 タブレット ¥ 7632.16 ¥ 704.41 ¥ 63396.66
  • 無料航空便配送
60 タブレット ¥ 3632.97 ¥ 728.66 ¥ 43719.57
  • 無料航空便配送
36 タブレット ¥ 725.14 ¥ 769.07 ¥ 27686.39
  • 無料航空便配送
24 タブレット ¥ 789.21 ¥ 18941.02

30mg

パッケージ 節約 あたり タブレット 価格 ご注文
90 タブレット ¥ 14555.58 ¥ 809.68 ¥ 72870.81
  • 無料航空便配送
60 タブレット ¥ 5819.32 ¥ 874.42 ¥ 52464.94
  • 無料航空便配送
36 タブレット ¥ 1453.92 ¥ 931.02 ¥ 33516.64
  • 無料航空便配送
24 タブレット ¥ 971.40 ¥ 23313.70
  • 無料航空便配送

Deflazacort tablets

What is this medicine?

Deflazacort a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

What should I tell my health care providers before I take this medicine?

They need to know if you have any of these conditions:

  • Hypersensitivity to deflazacort;
  • Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia;
  • Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal;
  • Alterations in Cardiovascular/Renal Function: elevated blood pressure and sodium, and for decreased potassium level;
  • Gastrointestinal Perforation: GI disorders;
  • Behavioral and Mood Disturbances: euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis;
  • Effects on Bones: decreases in bone mineral density;
  • Serious Skin Rashes;
  • Ophthalmic Effects: May include cataracts, infections, and glaucoma;
  • Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids.

How should I use this medicine?

The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally. Discontinue gradually when administered for more than a few day..

What may interact with this medicine?

  • Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage;
  • Avoid use of moderate or strong CYP3A4 inducers, as they may reduce efficacy.

What side effects may I notice from this medicine?

The most common adverse reactions are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.